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Abstract
Background: P16 DNA methylation is well known to be the most frequent event in cancer development. It has
been reported that genetic inactivation of P16 drives cancer growth and metastasis, however, whether P16 DNA
methylation is truly a driver in cancer metastasis remains unknown.
Results: A P16-specific DNA methyltransferase (P16-dnmt) expression vector is designed using a P16 promoter-specific
engineered zinc finger protein fused with the catalytic domain of dnmt3a. P16-dnmt transfection significantly decreases
P16 promoter activity, induces complete methylation of P16 CpG islands, and inactivates P16 transcription in the
HEK293T cell line. The P16-Dnmt coding fragment is integrated into an expression controllable vector and used to
induce P16-specific DNA methylation in GES-1 and BGC823 cell lines. Transwell assays show enhanced migration and
invasion of these cancer cells following P16-specific DNA methylation. Such effects are not observed in the P16 mutant
A549 cell line. These results are confirmed using an experimental mouse pneumonic metastasis model. Moreover,
enforced overexpression of P16 in these cells reverses the migration phenotype. Increased levels of RB phosphorylation
and NFκB subunit P65 expression are also seen following P16-specific methylation and might further contribute to
cancer metastasis.
Conclusion: P16 methylation could directly inactivate gene transcription and drive cancer metastasis.
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Background
P16 (CDKN2A or Ink4a) is one of the most frequently
deleted genes in cancer genomes and has been studied
extensively [1]. P16 germline mutation carriers have
been shown to have a greatly increased predisposition to
familial melanoma [2–4]. Recently, genetic inactivation
of P16 has been proven to be a driver for cancer metas-
tasis in mice [5].
While genetic alterations in P16 do occur, gene methy-
lation is far more prevalent in human cancers [6–10].
Studies have shown that P16 DNA methylation is
correlated with a decreased level of expression in tissues
[6–10] and is linked to the development and metastasis
of many cancers [11–15]. It is therefore highly likely that
P16 DNA methylation may play an important role in
cancer development.
It has been reported that artificial P16 DNA methyla-
tion induced through the insertion of alu motifs in-
creased the susceptibility of mice to developing cancer
[16]. However, whether P16 DNA methylation drives
cancer metastasis has not been characterized. In the
present study, a P16-specific DNA methyltransferase
(P16-dnmt) was used to directly inactivate P16 transcrip-
tion and the subsequent effects on proliferation, migra-
tion, and invasion of cancer cells were evaluated in vitro.
These results were further confirmed in immuno-deficient
mice. This study provides experimental evidence that
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strongly implicates P16 DNA methylation as a driver in
cancer metastasis.
Results
P16 DNA methylation directly inactivates gene
transcription
In order to determine whether P16 DNA methylation
directly inactivates gene transcription, a P16 promoter-
specific DNA methyltransferase (P16-dnmt) was initially
constructed using the pcDNA3.1_myc/His vector as de-
scribed in the methods section (Fig. 1a). Western blot
analysis confirmed that endogenous P16 was greatly
reduced in HEK293T cells 48 h following transient
transfection with the P16-dnmt vector (Fig. 1b). A
dual-luciferase reporter assay further illustrated that
P16 promoter activity was significantly inhibited in
the P16-dnmt-transfected cells (Fig. 1c). Notably,
methylation of CpG islands within both the P16
promoter and exon-1 regions was detected using de-
natured high performance liquid chromatography
(DHPLC) and bisulfite-sequencing (Fig. 1d and e). An
additional control lacking approximately 80 % of the
DNA methyltransferase activity (R882H mutant) was
constructed to evaluate the impact of steric hindrance
from P16-Dnmt DNA binding on gene transcription. As
expected, chromatin-immunoprecipitation (ChIP)-PCR
analysis showed that the mutant still bound with the P16
promoter DNA fragment (Fig. 2a), but did not induce P16
Fig. 1 P16-specific methyltransferase (P16-dnmt) induces methylation of P16 CpG islands and represses gene transcription in HEK293T cells. a
Construction of P16-dnmt using P16 promoter-specific seven-zinc finger protein (7ZFP) and the catalytic domain of mouse DNMT3a; b Western
blot analysis for P16-Dnmt and endogenous P16; c Reporter assay results following P16-dnmt transfection; d DHPLC methylation analysis of the
P16 promoter in HEK293T cells; the 392-bp methylated (M) and unmethylated (U) P16 fragments were detected at the partial denaturing
temperature of 57.0 °C; e bisulfite clone-sequencing results from HEK293T cells transiently transfected with P16-dnmt
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DNA methylation (Fig. 2b). Furthermore, its capacity to
repress P16 expression was sharply decreased in both
HEK293T and BGC823 cells (Fig. 2c and d). These data
suggest that P16 DNA methylation is directly responsible
for P16 repression as opposed to steric hindrance. Taken
together, these results indicate that P16-dnmt encodes an
active methyltransferase for P16 CpG islands, and P16
DNA methylation is sufficient to inactivate endogenous
P16 expression.
In order to specifically methylate P16 CpG islands, the
P16-dnmt coding-sequence was then integrated into the
pTRIPZ lentivirus vector carrying a ‘Tet-on’ switch to
allow the gene expression to be controlled. Expression
of P16-Dnmt protein was induced in GES-1 cells stably
transfected with the P16-dnmt pTRIPZ vector after
treatment with 0.25 μg/mL doxycycline for 3 days
(61KD; Fig. 3a). Significant inhibition of endogenous P16
expression was observed in Western blot and quantita-
tive RT-PCR analysis when compared to GES-1 cells
transfected with the dnmt3a and 7ZFP control vectors
(Fig. 3a and b). Confocal microscopy revealed that the
average density of nucleic P16 gradually decreased in the
P16-dnmt expressing cells (Fig. 3c). In fact, after treat-
ment with doxycycline for 3 and 7 days, P16 expression
levels were decreased by 21.4 % and 53.3 %, respect-
ively (P <0.001). Most importantly, intensive methy-
lation of P16 CpG islands was induced in the GES-
1 cells stably transfected with P16-dnmt and treated
with doxycycline, but not in cells transfected with
the control vectors, nor in cells that did not receive
doxycycline treatment (Fig. 3d). Similarly, P16 DNA
methylation and subsequent repression of P16 ex-
pression was also induced by P16-Dnmt in the
BGC823 cell line (Additional file 1: Figure S1).
ChIP-PCR analysis also showed that P16-Dnmt specific-
ally bound the P16 promoter, but not the P14 promoter
(Additional file 1: Figure S2). Similarly, ChIP-sequencing
confirmed that the P16-Dnmt binding fragment was only
detected in the promoter of P16-Dnmt/Myc antibody
immunoprecipitated DNA from the P16-dnmt-expressing
BGC823 cells, but not in the IgG control, nor the cells
transfected with the control vector (Fig. 4a, red fragment;
Additional file 2: File S1, Additional file 3: File S2,
and Additional file 4: File S3). Although most of the
P16-Dnmt binding fragments were found in intergenic
and intron sequences (Additional file 1: Figure S3A),
the main P16-Dnmt binding motif was found to
closely match the antisense strand of the targeted
fragment in the P16 promoter with a similarity of 21/23
(91.3 %) base pairs (Additional file 1: Figure S3C,
red-framed motif ). Genome-wide methylation analysis
of P16-Dnmt expressing BGC823 cells was performed
using an Infinium Methylation 450 K array. The results il-
lustrated that 647 of 481,615 informative CpG sites
Fig. 2 Comparison of DNA binding capacity, DNA methylation induction, and P16 expression levels between P16-dnmt and the R882H mutant in
HEK293T and BGC823 cells 72 h following transient transfection. a Chromatin-immunoprecipitation (ChIP)-PCR results comparing P16 promoter
DNA binding for P16-Dnmt and R882H protein; b Methylation-specific PCR (MSP) detecting methylated and unmethylated P16 alleles;
c Quantitative RT-PCR indicating P16 mRNA levels; d Western blot of P16 and Myc/P16-Dnmt protein levels
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(0.13 %) were significantly hypermethylated (Δβ >0.50).
Interestingly, 229 of these 647 CpG sites were located in
intragenic CpG islands and shores corresponding to
203 genes (Additional file 5: File S4). The targeted
P16 CpG island was included in the list of differentially
hypermethylated sites (Fig. 4a, blue arrow). Furthermore,
DNA methylation was not induced in the CpG islands
of two control genes, P14 (located within the same
CDKN2A locus as P16) and ZNF382 (located on a
different chromosome) (Fig. 4b). These results suggest
Fig. 3 P16 DNA methylation analysis of GES-1 cells stably transfected with the P16-dnmt pTRIPZ ‘Tet-on’ vector. a Western blot analysis of P16
and P16-Dnmt (61KD, arrow) and control vectors following treatment with 0.25 μg/mL doxycycline for 3 days. b Quantitative RT-PCR results for
the P16-dnmt stably transfected, doxycycline-treated cells. c Confocal analysis with P16 labeling following 3 and 7 days of doxycycline treatment.
d Confirmatory DHPLC methylation analysis of P16-specific methyltransferase expressing cells (arrow) and controls following 7 days of doxycycline
treatment. The 567-bp methylated (M) and unmethylated (U) P16 promoter fragments were analyzed at the partial denaturing temperature of
54.0 °C. DNA samples from HCT116 cells containing both the methylated and unmethylated P16 alleles were used as controls (M.&U.Ctrl)
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that doxycycline-induced P16-dnmt expression could
specifically methylate P16 CpG islands.
P16-specific DNA methylation promotes migration and
invasion of cancer cells
Various assays were then conducted to further
characterize the biological behaviors of cancer cells fol-
lowing P16-specific inactivation by DNA methylation.
Transwell assays revealed that the migration ability of
GES-1 and BGC823 cells was significantly increased fol-
lowing P16-specific DNA methylation (Fig. 5a and b).
Similarly, Matrigel assays showed that the invasion
capacity of these cell lines was also significantly enhanced
by P16-specific DNA methylation (Fig. 5c and d).
Four weeks after BGC823 cells stably transfected with
P16-dnmt were injected into the tail vein of the NOD
SCID mice, metastatic nodules were observed in the
lung (Fig. 6a). The average lung weight, which correlates
with the number of metastatic cells, in the P16-dnmt
group was 152.5 % that of the empty vector control
group (Mann–Whitney test, P <0.001; Fig. 6b). The aver-
age proportion of metastatic nodule area to total lung
area in the P16-dnmt group was also significantly higher
than the control group (P <0.004, Fig. 6c).
In addition, P16-specific DNA methylation was
found to slightly, but significantly, inhibit proliferation
of GES-1 cells, while the proliferation of BGC823
cells was not affected (Additional file 1: Figure S4).
However, growth inhibition of the P16-dnmt transfected
GES-1 cells was not observed in the SCID mice despite
detection of methylated-P16 alleles in the xenografts
(Additional file 1: Figure S5).
In order to confirm whether the enhanced migration
of cancer cells is P16 DNA methylation-specific, a rescue
Fig. 4 Characterization of the P16-Dnmt binding fragments and methylation status of the promoter CpG islands in P16 and control genes in
P16-dnmt stably transfected cells. a Chromatin-immunoprecipitation-sequencing (ChIP-Seq) and Illumina methylation 450 K array results in the
ink4a locus in BGC823 cells; b DHPLC methylation analysis of CpG islands in P14 and ZNF382 promoters in GES-1 cells expressing P16-Dnmt. DNA
samples with and without M.sssI methylation were used as methylated and unmethylated controls
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assay was carried out in the P16-dnmt expressing
BGC823 cells through transient transfection of a P16 ex-
pression vector. Results of the Transwell assay demon-
strated that enforced P16 overexpression significantly
reversed the enhanced migration phenotype of these
cells (Fig. 7a). Similar results were also observed in
HONE-1 cells (Additional file 1: Figure S6). In contrast,
downregulation of endogenous P16 expression through
transient siRNA transfection significantly enhanced the
migration of BGC823 and GES-1 cells (Fig. 7b). Further-
more, the migration capacity of A549 cells, which lack
P16 alleles, was not changed following stable transfec-
tion of P16-dnmt and 7 days of doxycycline treatment
(Fig. 7c). Taken together, these results imply that the en-
hanced migration and invasion phenotypes of cancer
cells are P16-specific.
Fig. 5 Migration and invasion assays carried out with cell lines stably transfected with the P16-dnmt pTRIPZ vector in vitro. a, b Results of
Transwell migration assays for GES-1 and BGC823 cell lines following 48-h and 36-h incubation, respectively; c, d Results of Matrigel invasion as-
says for GES-1 and BGC823 cell lines following 108-h and 96-h incubation, respectively; the average cell number and s.d. are displayed (Right).
Dox (+), with 0.25 μg/mL doxycycline treatment; Dox (−), without doxycycline treatment. These experiments were independently repeated
in triplicate
Fig. 6 P16-specific methylation promotes experimental pneumonic metastasis of BGC823 cells. a Images of representative metastatic nodules in
the lung of SCID mice (H&E staining). b The lung weights of mice in the P16-dnmt pTRIPZ and control groups at day 19. c The ratio of metastatic
nodule area to lung area of mice in the P16-dnmt pTRIPZ and control groups
Cui et al. Genome Biology  (2015) 16:252 Page 6 of 12
P16-specific DNA methylation promotes RB
phosphorylation and upregulates NFκB subunit P65
expression
To confirm that P16 DNA methylation affects its down-
stream signal pathway, P16-CDK4/6-RB, the phosphoryl-
ation level of RB protein was analyzed using Western blot
analysis. As expected, increased levels of phosphorylated
RB were detected in the P16-dnmt transfected BGC823
and GES-1 cells treated with doxycycline when compared
to those without doxycycline induction and those trans-
fected with the control vector. Total RB protein levels
were not changed (Fig. 8a and b). Furthermore, the ex-
pression level of nuclear factor NFκB subunit P65 was also
increased in the P16-dnmt transfected cells.
Discussion
It is well known that methylation of CpG islands around
transcription start sites is inversely correlated with the
Fig. 7 Effect of varying P16 expression on migration. a Rescue assay demonstrating the effect of enforced P16 overexpression on migration of the
P16-dnmt stably transfected BGC823 cells treated with doxycycline for 2 weeks. b Migration assay results after 24-h and 48-h transient siRNA transfection in
GES-1 and BGC823 cell lines. P16 qRT-PCR results are also presented. c Migration capacity of A549 cells (lacking P16 alleles) following stable transfection of
P16-dnmt. After treatment with 0.25 μg/mL doxycycline for 1 week, these cells (4.0 × 104) were seeded into each well and incubated for 28 h. Western blot
analysis of P16-Dnmt and P16 expression is also presented. Migration assays were independently repeated in triplicate
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expression level of genes in many cells and tissues. P16
DNA methylation may occur as a long-term mechanism
to maintain gene suppression following transcriptional
silence induced by repressive histone modifications [17].
Whether P16 promoter methylation alone is capable of
silencing transcription has not been well studied. In the
present study, we found that P16-Dnmt-induced methy-
lation of P16 CpG islands could directly inactivate gene
expression and promote metastasis of cancer cells.
Studies have shown that target-specific methylation/
demethylation is associated with transcriptional inactiva-
tion/re-activation of several other human genes [18–20].
Zhang et al. reported that P16-specific artificial tran-
scription factor (P16-ATF) could induce P16 DNA de-
methylation and re-activate its expression [21]; however,
it is not known whether DNA demethylation is essential
for re-activation of this gene. Yu et al. successfully estab-
lished a p16 DNA methylation model in mice through
the insertion of alu motifs into the mouse p16 promoter
and found subsequent gene inactivation [16]; however,
the possibility that the insertion of alu motifs directly
contributed to transcriptional repression cannot be ex-
cluded. In order to increase the targeting specificity in
the present study, we employed the pTRIPZ vector that
allowed for controllable expression of P16-Dnmt. Our
results showed that P16-Dnmt-induced DNA methyla-
tion was sufficient to silence transcription in two hu-
man gastric epithelial cell lines. This result is consistent
with a recent report which demonstrated that engineered
transcription activator-like effector (TALE)–Dnmts induced
P16 DNA methylation, inactivated gene expression, and in-
creased replication in human fibroblasts [22]. Additionally,
steric hindrance from P16-Dnmt DNA binding does not
appear to play a significant role in repressing gene tran-
scription as was demonstrated using the P16-dnmt R882H
mutant control. Taken together, the evidence suggests that
P16 DNA methylation primarily accounts for the inactiva-
tion of P16 transcription.
Genome-wide CRISPR screens in mouse models have
shown that genetic p16 inactivation may be a driver for
tumor growth and metastasis [5]. Luo et al. have re-
ported that the proportion of methylated P16 alleles is
significantly associated with metastasis of gastric cancers
[13]. Zhang et al. have also suggested that re-activation
of methylated P16 by P16-ATF inhibits migration and
invasion in AGS and H1299 cancer cell lines [21]. Here,
we have provided evidence to demonstrate that P16-Dnmt
mediated DNA methylation might promote metastasis of
cancer cells in vitro and in vivo. Moreover, we found that
such an effect was not observed in A549 cells lacking P16
alleles, and siRNA downregulation of P16 expression also
promoted the migration of cell lines, and overexpression
of P16 reversed the cell migration phenotype. These facts
strongly implicate inactivation of P16 by DNA methyla-
tion as a possible promoter of migration/invasion and me-
tastasis of cancer cells.
Inactivation of the P16 gene results in higher cyclin
D-dependent protein kinase activity and thus induces
aberrant phosphorylation of RB protein. Therefore normal
cell cycle checkpoints are bypassed allowing accelerated
Fig. 8 Western blot analysis of P16, RB, phosphorylated RB, and NFκB subunit P65 expression in the P16-dnmt stably transfected cells. BGC823
and GES-1 cell lines were tested 14 and 8 days following doxycycline treatment, respectively. a WB image; b Relative density of tested protein
bands normalized against GAPDH
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cell growth and increased genomic instability [23, 24]. We
found that the induction of P16-specific DNA methylation
could also increase the phosphorylation of RB.
NFκB subunit P65 is the master regulator in the
senescence-associated secretary phenotype (SASP) [25].
In melanomas, the expression of P65 is increased while
P16 expression is decreased [26]. P65 also regulates the
transcription of a group of metastasis-related genes, in-
cluding MMP-9/2 [27–29]. In this study, we also found
that induction of P16 DNA methylation also increases
the amount of P65 protein in cancer cells. Additional
studies are required to determine other pathways in-
volved in the P16 DNA methylation-related metastasis
phenotype.
Conclusion
Engineered zinc finger protein-targeted P16 DNA methy-
lation directly inactivates P16 expression and promotes
invasion and metastasis of cancer cells.
Methods
Cell lines and cultures
HEK293T, BGC823, and GES-1 cell lines were kindly
provided by Professor Yang Ke at Peking University
Cancer Hospital and Institute. The A549 cell line lacking
the P16 locus was kindly provided by Professor Zhiqian
Zhang at the same institute. The HONE-1 cell line
was kindly provided by Professor Zhen Sun at
Capital Medical University School of Stomatology,
Beijing. All of these cell lines were tested and au-
thenticated using the Goldeneye20A STR Identifiler
PCR Amplification Kit (Beijing Jianlian Genes Technology
Co., Ltd.) before being used in this study [30]. These
cell lines were cultured in RPMI1640 medium supple-
mented with 10 % FBS and maintained at 37 °C in
humidified air with 5 % CO2. Cell proliferation was an-
alyzed using the Cell Counting Kit-8 (CCK-8) [21].
Construction of vectors and transfection
The P16-dnmt plasmid was constructed by fusing a
SP1-like engineered seven-zinc finger protein (7ZFP)
6I capable of specifically binding the 21-bp fragment
(5′-GAG GAA GGA AAC GGG GCG GGG-3′, in-
cluding a Sp1-binding site) within the human P16
promoter [21] with the catalytic domain (approxi-
mately 608–908aa) of mouse dnmt3a in the pFast Bac
HT A-dnmt3a vector (kindly provided by Professor
Keith Robertson at Georgia Regents University, USA)
[31]. Point mutation R882H in the catalytic domain
of Dnmt3a is the most frequent somatic mutation
in acute myeloid leukemia [32]. The methyltransfer-
ase activity of R882H DNMT3A is reduced by ap-
proximately 80 % compared with the wide-type [33].
Thus, a P16-dnmt R882H mutant control was
constructed as a negative control. The P16-dnmt
coding sequence was integrated into a pcDNA3.1 vector
and an expression controllable pTRIPZ vector carrying a
‘Tet-on’ switch (Open Biosystem, USA), respectively. Con-
trol vectors for the Dnmt3a catalytic domain or 7ZFP(6I)
were also constructed. The purified P16-dnmt plasmid
DNA was mixed with VSVG and Δ8.9 (Addgene, USA) to
prepare lentivirus transfection particles. The P16 expres-
sion vector was constructed using wild-type P16 coding
sequence cDNA and integrated into the pIRES2-EGFP
vector. The cells (4.5 × 104) were transiently transfected
with the pIRES2-P16 expression vector, seeded into each
well, and incubated for 43 h. P16 specific siRNAs (5′-
CCGUA AAUGU CCAUU UAUAT T-3′ and 5′-UAUAA
AUGGA CAUUU ACGGT T-3′) were synthesized
(GenePharma) and used to transiently transfect cells at
a final concentration of 1.0 μg/1 mL. The scramble siR-
NAs (5′-UUCUC CGAAC GUGUC ACGUT T-3′ and
5′-ACGUG ACACG UUCGG AGAAT T-3′) were used
as negative control. The fresh lentivirus particles were
used to transfect human cells.
Bisulfite-DHPLC, −sequencing, MethyLight, and
methylation-specific PCR (MSP)
The 392-bp fragments isolated from the antisense-strand
of P16 exon-1 in cultured cells were amplified with a
CpG-free primer set and analyzed using DHPLC and
clone sequencing as described previously [13, 34];
however, the PCR annealing temperature was fixed at
57.0 °C to avoid amplification bias between methyl-
ated and unmethylated P16 alleles. The 567-bp frag-
ment in the antisense-strand of the P16 promoter was
also amplified using a CpG-free primer set (forward,
5′-gaatt agggt ttttg attta gtgaa tt-3′; reverse, 5′-accct
atccc tcaaa tcctc taaa-3′) at an annealing temperature of
65 °C, analyzed at the partial denaturing temperature of
54 °C in DHPLC analysis, and confirmed using clone
sequencing. Methylated and unmethylated P16 were also
analyzed by 150/151-bp MSP [35].
The 272-bp P14 CpG island fragment was amplified
using a CpG-free primer set (forward, 5′-gttgt ttatt tttgg
tgtta-3′; reverse, 5′-acctt tccta cctaa tcttc-3′) at the
annealing temperature of 51.0 °C, and analyzed at the
partial denaturing temperature of 57.7 °C in DHPLC
analysis. The 437-bp ZNF382 CpG island fragment was
amplified and analyzed by DHPLC as previously de-
scribed [30].
Quantitative RT-PCR, Western blot, and confocal analysis
of P16 expression
The P16 mRNA and protein level in cell lines were ana-
lyzed as described [21].
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Chromatin immunoprecipitation (ChIP) assays
The 124-bp P16 and 61-bp P14 DNA fragments within
CpG islands bound to P16-Dnmt were quantitated as
described [21, 36]. Anti-Myc antibody was used to
precipitate P16-Dnmt protein containing a Myc tag. The
Myc-ChIPed-DNA samples were sequenced using the
Illumina HiSeq2500 (Shanghai Biotechnology Co., China).
The readouts were preprocessed using online fastx software
(version 0.0.13; http://hannonlab.schl.edu/fastx_toolkit/
index.html), mapped to the human genome hg19
using Bowties (version o.12.8) [37], and enriched
using MACS (version 1.4.2) [38]. The protein-binding
motif was identified using MEME software [39]. The
detected peaks/annotated information is presented as
Additional file 2: File S1, Additional file 3: File S2,
and Additional file 4: File S3.
Genome-wide analysis of DNA methylation
Illumina Infinium HD Methylation450K arrays were
used to perform differential CpG methylation analyses
on BGC823 cells stably transfected with the P16-dnmt
and pTRIPZ control vectors following 14 days of doxy-
cycline treatment according to the Assay Manual. Two
parallel samples were tested for each group. DNA
methylation levels for each CpG site were computed as
the ratio of normalized methylated signal intensity to the
sum of methylated and unmethylated signal intensities
using GenomeStudio software. Using the control vector
as a reference, Δβ was calculated to represent differential
methylation for each CpG site in the P16-dnmt ex-
pressing cells. The differential methylation was con-
sidered to be significant when the Δβ value was >0.50.
The raw methylation data are available as Additional
file 6: File S5.
Dual-luciferase reporter assay
The P16 promoter (approximately −597 to +155 nt) was
integrated into the pGL3-Basic vector and used for pro-
moter activity analysis as previously described [21].
Transwell migration and Matrigel invasion tests
The Transwell migration and Matrigel invasion tests
were performed using GES-1 and BGC823 cells sus-
pended in 150 μL serum-free medium (2 × 105 cells/
mL). The BGC823 cells were incubated for 36 h and 96
h at 37 °C in 5 % CO2 before quantifying their migra-
tion and invasion capacity, respectively. Similarly, the
GES-1 cells were quantified following 48-h and 108-h
incubation, respectively [21]. Wound healing status was
dynamically recorded using the IncuCyte ZOOM™ live-
cell imaging platform. Each trial consisted of three in-
dependent samples, and all the assays were repeated
two to three times.
Xenografts and pneumonic metastases in SCID mice
GES-1 cells (1.4 × 106 cells in 200 μL Matrigel suspen-
sion) were stably transfected with the P16-Dnmt or con-
trol vector, induced with 0.25 μg/mL doxycycline for 7
days, and then injected subcutaneously into the lower
limb of NOD SCID mice (female, 5 weeks old, weight
10–20 g, purchased from Beijing Huafukang Biotech).
The mice were provided distilled, sterile water contain-
ing 2 μg/mL doxycycline. These mice were sacrificed 48
days after transplantation. The weight and volume of tu-
mors were then analyzed.
For the pneumonic metastasis assay, BGC823 cells
stably transfected with the P16-dnmt or control vector
were also induced with 0.25 μg/mL doxycycline for 7
days, and then injected into the tail vein of the SCID
mice (1.5 × 106 cells in 0.15 mL medium) (10 randomly
allocated mice per group). The lung weight was detected
at the 19th experimental day for each mouse [40]. The
lung organs were fixed with Bouin solution, paraffin-
embedded and cut into 5 μm slides along the maximum
area, and examined microscopically following H&E
staining. The lung area and total tumor nodule area
were measured using INFINITY Analyze (Version 4.0,
Lumenera Sci). The nodule area to the lung area ratio
was calculated for each mouse.
Statistical analysis
Results were displayed by constituent ratios of enumeration
or ranked data. All P values were two-sided, and a differ-
ence with P <0.05 was considered statistically significant.
Ethical approval
This study was approved by the institute’s animal ethics
committee (approval no. AE-2012-06).
Data and materials availability
The methylation array data have been deposited into the
Gene Expression Omnibus under accession number
GSE74233. The ChIP-sequencing raw data have been de-
posited into the bioproject database under accession
number SRA306603.
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